Gujarat Themis Biosyn Limited issued a corrigendum to its Notice of the 45th Annual General Meeting (AGM) that was circulated to members on September 4, 2026. The AGM is scheduled to be held on Wednesday, September 30, 2026, at 12:30 p.m. (IST) at 69/A, GIDC Industrial Estate, Vapi-396195, Dist. Valsad, Gujarat.

The corrigendum specifically amends Resolution No. 8 and its explanatory statement concerning the proposal to raise funds through a preferential issue of equity shares. The amendments were made to align with the applicable provisions of the SEBI ICDR Regulations.

Key Amendments to Resolution No. 8:

1. Issue Details:

  • The number of equity shares to be issued is revised to 82,92,081 shares of face value ₹1 each.
  • The issue price is set at ₹404 per equity share (including a premium of ₹403 per share).
  • The total issue size is ₹335,00,00,724 (₹335.00 crores).

2. Allottee Details:

The table detailing the proposed allottees is updated with revised share allotments and amounts, though the allottee names remain unchanged:

| No. | Name of Investor | No. of Shares | Amount (₹) | Category |

| 1 | Pharmaceutical Business Group (India) Limited | 61,88,121 | 250,00,00,884 | Promoter Group |

| 2 | Yusuf Khwaja Hamied | 2,47,526 | 10,00,00,504 | Public |

| 3 | Special Situation India Fund | 4,64,108 | 18,74,99,632 | Public |

| 4 | India Special Assets Fund III | 6,90,594 | 27,89,99,976 | Public |

| 5 | ISAF III Onshore Fund | 7,01,732 | 28,34,99,728 | Public |

3. Objects of the Issue:

The utilization of proceeds and timeline table is replaced for clarity:

| Sr. No. | Object | Amount (₹) | Timeline |

| 1 | Redemption of Non-convertible Debentures (NCDs) and/or repayment/prepayment of borrowings and interest for payment of consideration and cost of acquisition of 100% equity stake in MicroBiopharm Japan Co., Ltd. (including investment in the Company's subsidiary in Japan) | 310,00,00,724 | 12 months |

| 2 | General Corporate Purposes (not exceeding 25%) | 25,00,00,000 | 12 months |

| Total | | 335,00,00,724 | |

4. Interim Use of Proceeds:

The text is replaced to state that pending utilization, the issue proceeds will be invested in deposits with scheduled commercial banks, government securities, or other permitted creditworthy instruments.

5. Monitoring Agency:

India Rating and Research Private Limited, a SEBI-registered agency, is appointed to monitor the utilization of the issue proceeds.

6. Relevant Date:

The Relevant Date for price calculation is confirmed as August 31, 2026.

7. Price Justification:

The floor price is calculated as ₹403.82 per share, being the higher of:

  • The 90-day volume weighted average price (VWAP) preceding the Relevant Date: ₹384.09
  • The 10-day VWAP preceding the Relevant Date: ₹403.82

The issue price of ₹404 is not less than this floor price.

8. Shareholding Pattern Impact:

The post-issue shareholding pattern table is updated:

  • Pre-issue total shares: 13,01,51,705
  • Post-issue total shares: 13,84,43,786
  • Promoter & Promoter Group holding: Increases from 59.33% (7,72,18,083 shares) to 60.25% (8,34,06,204 shares)
  • Public shareholding: Decreases from 40.67% (5,29,33,622 shares) to 39.75% (5,50,37,582 shares)

9. Allottee Shareholding Post-Issue:

The table showing the pre and post-allotment holding of the proposed allottees is updated. Notably, Pharmaceutical Business Group (India) Limited's holding will increase from 38.97% (5,07,16,440 shares) to 41.08% (5,69,04,561 shares). The other four allottees, who currently hold nil shares, will receive their respective allotments.

The corrigendum states that the changes are primarily due to rectifying an error in the floor price calculation and are in the interest of the company. There are no material changes beyond those specified. This corrigendum forms an integral part of the AGM notice and will be circulated to members electronically and made available on the stock exchanges' and company's websites.

All other contents of the AGM notice remain unchanged.